Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy

References

• National Institute of Diabetes, Digestive and Kidney Disorders. Available from http://diabetes.niddk.nih.gov/dm/pubs/statistics#7 [Last accessed 5 June 2007]
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917–32
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27: 17–20
   Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335–42
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2007. Diabetes Care 2007;30(Suppl 1):S4–41
   PubMedGoogle Scholar
• AACE Diabetes Medical Guidelines Task Force. AACE diabetes guidelines. Endocr Pract 2002;8(Suppl 1):41–65
   Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–9
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 1993;329:977–86
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711–21
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352: 837–53
   Google Scholar
• Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994;17:267–74
   PubMed Web of Science ®Google Scholar
• Glasgow RE, Ruggiero L, Eakin EG, et al. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997;20:562–7
   PubMed Web of Science ®Google Scholar
• Van der Does FE, De Neeling JN, Snoek FJ, et al. Randomized study of two different levels of glycemic control within the acceptable range in type 2 diabetes. Diabetes Care 1998;21:2085–93
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26: 881–5
   Google Scholar
• Ceriello A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005;54:1–7
   PubMed Web of Science ®Google Scholar
• Unger RH. Glucagon physiology and pathophysiology. NEJM 1971;285:443–9
   PubMed Web of Science ®Google Scholar
• Young AA. Amylin’s physiology and its role in diabetes. Curr Opin Endocrinol Diab 1997;4:282–90
   Google Scholar
• Young AA, Gedulin BR, Vine W, et al. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995;38:642–8
   PubMed Web of Science ®Google Scholar
• Gedulin BR, Rink TJ, Young AA. Dose-response for glucagono-static effect of amylin in rats. Metabolism 1997;46:67–70
   Google Scholar
• Rushing PA, Lutz TA, Seeley RJ, et al. Amylin and insulin interact to reduce food intake in rats. Horm Metab Res 2000;32:62–6
   PubMed Web of Science ®Google Scholar
• Kruger DF, Aronoff SL, Edelman SV. Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostatis. Diabetes Educ 2007;33 (Suppl 2):32S–48
   Google Scholar
• Kong MF, Stubbs TA, King P, et al. The effect of a single dose of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998:41:577–83
   PubMed Web of Science ®Google Scholar
• Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838–48
   PubMed Web of Science ®Google Scholar
• Hollander PA, Levy P, Fineman MS, et al. Pramlintide therapy as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2003;26:784–90
   PubMed Web of Science ®Google Scholar
• Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189–95
   PubMed Web of Science ®Google Scholar
• Symlin [package insert]. San Diego, CA, USA. Amylin Pharmaceuticals, 2005
   Google Scholar
• Whitehouse F, Kruger DF, Fineman MS, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724–30
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey R, Fineman MS, et al. Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a one-year randomized controlled trial. Diabet Med 2004;21:1204–12
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Assessing health-related quality of life (HRQOL): the Insulin Delivery System Questionnaire (IDSRQ). Diabetes Care 2005;28:53–8
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. London: Academic Press, 1969
   Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92
   Google Scholar